HC Wainwright Estimates MannKind’s Q2 Earnings (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) – Equities researchers at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of MannKind in a note issued to investors on Wednesday, July 16th. HC Wainwright analyst anticipates that the biopharmaceutical company will earn $0.05 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share. HC Wainwright also issued estimates for MannKind’s Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.05 EPS.

MannKind (NASDAQ:MNKD) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. MannKind had a negative return on equity of 32.41% and a net margin of 10.12%. The business had revenue of $78.35 million for the quarter, compared to the consensus estimate of $75.86 million. During the same period in the previous year, the business earned $0.05 EPS. MannKind’s revenue was up 18.1% compared to the same quarter last year.

Several other research firms have also recently commented on MNKD. Mizuho started coverage on MannKind in a research note on Thursday, April 10th. They issued an “outperform” rating and a $12.00 target price for the company. Wall Street Zen upgraded MannKind from a “hold” rating to a “buy” rating in a research report on Friday. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, MannKind has a consensus rating of “Buy” and a consensus price target of $10.14.

MannKind Stock Performance

Shares of NASDAQ:MNKD opened at $3.76 on Friday. The business has a fifty day moving average of $4.02 and a 200-day moving average of $4.88. MannKind has a twelve month low of $3.51 and a twelve month high of $7.63. The firm has a market cap of $1.14 billion, a PE ratio of 37.60 and a beta of 0.96.

Insider Buying and Selling

In other news, EVP David Thomson sold 32,179 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total transaction of $150,597.72. Following the completion of the sale, the executive vice president owned 772,427 shares of the company’s stock, valued at $3,614,958.36. This represents a 4.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven B. Binder sold 80,144 shares of the business’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $4.69, for a total transaction of $375,875.36. Following the completion of the sale, the director directly owned 1,006,611 shares in the company, valued at $4,721,005.59. This represents a 7.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 266,198 shares of company stock worth $1,143,244. Insiders own 2.70% of the company’s stock.

Institutional Trading of MannKind

Institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in MannKind in the 4th quarter valued at approximately $37,000. Farther Finance Advisors LLC grew its stake in shares of MannKind by 1,379.2% during the 2nd quarter. Farther Finance Advisors LLC now owns 7,396 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 6,896 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new stake in shares of MannKind in the fourth quarter valued at approximately $65,000. Blueshift Asset Management LLC bought a new stake in shares of MannKind in the first quarter worth $51,000. Finally, Proficio Capital Partners LLC acquired a new position in MannKind during the fourth quarter worth $70,000. 49.55% of the stock is currently owned by institutional investors.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.